IMVARIA, a health tech company pioneering AI-driven digital biomarker solutions, announced strategic investments from new and existing investors to accelerate IMVARIA's growth and fuel innovation in AI-driven digital healthcare. InHealth Ventures, an early-stage fund linked to leading screening and diagnostics provider InHealth Group, led the funding, with participation from the Labcorp Venture Fund and existing partner Cedar Crest Holdings. The new strategic investments will enable IMVARIA to extend its AI-driven diagnostic services for various forms of lung disease and make IMVARIA's tests more easily accessible for clinicians, especially pulmonologists.